3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Breast Neoplasms
4
Urothelial Cancer
2
Urinary Bladder Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
1
Non Small Cell Lung Cancer NSCLC
1
Nasopharyngeal Carcinoma
1
Metastatic Urothelial Cancer
1
Metastatic Adenocarcinoma of the Pancreas
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Bile Duct Neoplasms
1
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Non Small Cell Lung Cancer NSCLC
×
Gemcitabine
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA